Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Receivables (2023 - 2025)

CG Oncology's Receivables history spans 3 years, with the latest figure at $688000.0 for Q4 2025.

  • For Q4 2025, Receivables changed N/A year-over-year to $688000.0; the TTM value through Dec 2025 reached $688000.0, changed N/A, while the annual FY2025 figure was $688000.0, N/A changed from the prior year.
  • Receivables reached $688000.0 in Q4 2025 per CGON's latest filing, up from $515000.0 in the prior quarter.
  • In the past five years, Receivables ranged from a high of $688000.0 in Q4 2025 to a low of $92000.0 in Q4 2023.
  • Average Receivables over 3 years is $334250.0, with a median of $263500.0 recorded in 2024.
  • The largest YoY upside for Receivables was 275.91% in 2025 against a maximum downside of 125.49% in 2025.
  • A 3-year view of Receivables shows it stood at $92000.0 in 2023, then soared by 48.91% to $137000.0 in 2024, then skyrocketed by 402.19% to $688000.0 in 2025.
  • Per Business Quant, the three most recent readings for CGON's Receivables are $688000.0 (Q4 2025), $515000.0 (Q3 2025), and $562000.0 (Q2 2025).